Schäfer is expected to take up the new position in spring 2017.
By appointing a scientist to its executive board, the Danish company said it was placing innovation and science as a critical area for securing growth.
Its product portfolio includes cultures, enzymes, probiotics and natural colours.
Schäfer has more than 20 years’ experience in industrial microbiology, R&D and innovation under his belt, has published several papers and is the co-author of a number of patents.
CEO of Chr. Hansen Cees de Jong said Schäfer was a skilled and business-oriented technology leader with international experience.
“The overall goal of the R&D Microbial Platform is to secure a common and strong scientific backbone within industrial microbes that can sustain new innovations for the food cultures & enzymes and health & nutrition business units and support Chr. Hansen’s undisputed leadership in bacterial fermentation technology,” de Jong added.
Chr. Hansen counts over 2,800 employees across more than 30 countries worldwide.
For2015/2016 last financial year it reported revenue of €949 million.